An Open Label Clinical Study to Evaluate the Therapeutic Effect of Abhrakabhasmadi Yoga in Madhumeha W.S.R to Type II Diabetes Mellitus

1Dr.Divya Naik, 2Dr.Aniruddha
1PG Scholar, 2Associate Professor
1Department of PG and PhD Studies in Kayachikitsa and Manasaroga
1Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital, Kuthpady, Udupi, 574118, Karnataka, India.

ABSTRACT
Madhumeha, one of the ashtamahagadas, is a santarpanottha vikara, and may be due to avarana or swavardhaka hetus and is chronic in nature. All types of prameha when neglected in the initial phase leads to madhumeha. Based on the symptoms of Madhumeha, it can be understood as Diabetes Mellitus. Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body’s systems, in particular the blood vessels and nerves.

Objective: to evaluate the therapeutic effect of abhrakabhasmadi yoga in madhumeha.

Methodology: open label clinical study with pre and post-test design. 20 patients diagnosed with madhumeha (type 2 diabetes mellitus) were taken for the study from Sri Dharmasthala Manjunatheshwara Ayurveda Hospital, Udupi, Karnataka. Intervention included administering 5gms abhrakabhasmadi yoga in the morning with madhu before food for 28 days. The parameters were assessed before and after treatment.

Results: Results were statistically analysed using paired t test and Wilcoxon sign rank test and were statistically significant.

Conclusion: The study revealed positive outcomes and proved that the formulation was successful in reducing FBS, PPBS, FUS, PPUS and symptoms of madhumeha.

Key words: madhumeha; diabetes mellitus; abhrakabhasmadi yoga

INTRODUCTION
Madhumeha is a santarpanottha vikara and the samprapthi may be due to avarana or swavardhaka hetus. It is also included in ashtamahagadas. As the disease is chronic in nature it is also addressed as prameho anushanginam. It involves all the three dosha and ten dushya that includes meda, rakta, shukra, ambu, vasa, lasika, majja, rasa, ojas and mamsa. The result of aparipakva kapha formed due to indulgence of etiological factors with meda proceed downward through the matravaha srotas and gets settled at basti mukha leading to prabhoota mutrata, avila mutrata etc symptoms. All types of prameha when neglected in the initial phase leads to madhumeha. Based on the symptoms of Madhumeha, it can be understood as Diabetes Mellitus.
Diabetes mellitus is a chronic disease caused by inherited and/or acquired deficiency in production of insulin by the pancreas, or by the ineffectiveness of the insulin produced. Such a deficiency results in increased concentrations of glucose in the blood, which in turn damage many of the body’s systems, in particular the blood vessels and nerves.

Diabetes is a growing challenge in India with estimated 8.7% diabetic population in the age group of 20 and 70 years. The rising prevalence of diabetes is driven by a combination of factors – rapid urbanization, sedentary lifestyles, unhealthy diets, and increasing life expectancy. India currently represents 49% of the world’s diabetes burden, with an estimated 72 million cases in 2017. With a pre diabetes prevalence of 10.3% among adults, people with diabetes in India are likely to more than double in the next decade. The ultimate aim is, a good control and management of Madhumeha and thus reducing the risk of the development of complications.

There are many studies done to evaluate the efficacy of ayurvedic formulations in prameha/madhumeha showing positive results. However, study of formulations with both herbal and mineral origin drugs can be done to get best outcome owing to their independent attributes as well as their synergetic action, hence this study is taken up.

MATERIALS AND METHODS

Objective of the study:

To evaluate the therapeutic effect of abhrakabhasmadi yoga in madhumeha w.s.r to type 2 diabetes mellitus.

Design:


Setting:

Sri Dharmasthala Manjunatheshwara Ayurveda Hospital, Kuthpady, Udupi.

Participants:

From August 2020 to January 2021, 20 patients with fasting Plasma Glucose ≥126 mg/dl (7.0 mmol/l), two-hour plasma glucose ≥ 200mg/dl, with or without the association of symptoms of Madhumeha like Prabhootamutra, Avila mutrata, kshut and pipasa adhikya were taken up for the study.

Diagnostic criteria:

1. Fasting Plasma Glucose ≥126 mg/dl (7.0mmol/l). Fasting is defined as no caloric intake for at least 8-10 Hours.
2. Two - hour plasma glucose ≥ 200mg/dl, with or without the association of Symptoms of Madhumeha like prabhootamutra, Avila mutrata, kshut, pipasa adhikya etc.

Inclusion criteria:

1) Patients fulfilling the diagnostic criteria
2) Patients between the age group of 30 to 70 years of either sex.
3) Fasting Plasma Glucose Level ranging from 126mg/dl to 200 mg/dl or Post Prandial Plasma Glucose level ranging from 200 to 350mg/dl.
4) Patients who are already on other anti-diabetic drugs after discontinuing the treatment and after the washout period of one week.
5) Both participant and caregiver are willing and able to provide informed consent.

Exclusion criteria:

1) Type 1 DM.
2) Diabetic Cardiomyopathy, Neuropathy, Nephropathy, Retinopathy, and Diabetic ketoacidosis
3) CNS disorders e.g. Encephalopathy.
4) Any major concomitant illness or hospitalization for MI, Cardiovascular disease, CKD, Gastrointestinal disease (especially - Chronic Intestinal disease, IBD, Intestinal Ulceration) carcinoma, HIV, TB etc.

5) Pregnant & Lactating women.

6) Had participated in any clinical trial within 3 months of screening.

**Intervention:**

Patients were administered 5gm of *Abhrakabhasmadi yoga* in the morning, 30 mins before food with *madhu* for 28 days and followed up on 14th and 56th day. The total duration of study was 56 days.

**Assessment criteria:**

Objective and Subjective criteria were scored by standard method and were assessed before, and after treatment on 0th and 28th days. Follow up done on 14th and 56th day.

**Statistical analysis:**

Results were statistically analysed using paired t test and Wilcoxon sign rank test for objective and subjective parameters respectively.

**Primary outcome/objective parameters:**

- Fasting Plasma Glucose Level
- Post Prandial Plasma Glucose Level
- Fasting urine sugar level
- Post Prandial urine sugar level

**Secondary outcome/subjective parameters:**

- Atibhubuksha.
- AtiMutrapravritti.
- AtiTrishna.
- Dourbalya
- Mukhatalushosha
- Kara padadaha
- Kara padasuptata
- Shithilangata

**Results:**

The overall percentage of improvement in FBS was 13.79%, was 18.11% in PPBS, 36.428% in FUS, and 38.554% improvement in PPUS. There was significant reduction in symptoms with the overall percentage of improvement in atimutrata of 41.463%, 35.555% in atibubuksha, 44.117% in atitrusha, 52.941% in mukatalushosha, 33.333% in karapadadaha, 39.13% in karapadasuptata, 33.333% in daurbalya and 40% improvement in shithilangatha.

Effect of treatment in objective parameters are shown in table no. 1 and subjective parameters are shown in table no. 2

**Overall effect of the treatment:**

There was moderate remission in 50% of patients, mild remission in 25% of patients, good remission in 20% of patients and excellent remission in 5% of patients i.e 10, 5, 4 and 1 patient(s) respectively. Overall effect of treatment is shown in table no. 3
### Table no. 1 Effect of treatment on objective parameters

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Time</th>
<th>Mean ± SD</th>
<th>±SE</th>
<th>Difference in mean</th>
<th>% improvement</th>
<th>paired t test</th>
<th>t value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FBS 92 - 270 N = 20</td>
<td>BT</td>
<td>162.4 ± 27.683</td>
<td>6.190</td>
<td>22.4</td>
<td>13.793%</td>
<td>t = 2.589</td>
<td>P = 0.018</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>140 ± 40.057</td>
<td>8.957</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPBS 114 – 429 N = 20</td>
<td>BT</td>
<td>264.200 ± 46.248</td>
<td>10.341</td>
<td>47.850</td>
<td>18.11%</td>
<td>t = 2.892</td>
<td>P = 0.009</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>216.350 ± 73.461</td>
<td>16.426</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FUS 0.0 – 1.1 N = 7</td>
<td>BT</td>
<td>0.280 ± 0.423</td>
<td>0.0945</td>
<td>0.102</td>
<td>36.428%</td>
<td>t = 2.553</td>
<td>P = 0.019</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>0.177 ± 0.310</td>
<td>0.0693</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Table no. 2 Effect of treatment on subjective parameters

<table>
<thead>
<tr>
<th>Range</th>
<th>time</th>
<th>Mean ± SD</th>
<th>±SE</th>
<th>Difference in mean</th>
<th>% improvement</th>
<th>W.S.R.T*</th>
<th>z value</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atibubuksha 0 – 3 N = 17</td>
<td>BT</td>
<td>2.250 ± 1.070</td>
<td>0.239</td>
<td>0.800</td>
<td>35.555%</td>
<td>3.418</td>
<td>P = &lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>1.450 ± 0.887</td>
<td>0.198</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atimutrat 0 – 3 N = 18</td>
<td>BT</td>
<td>2.050 ± 0.759</td>
<td>0.170</td>
<td>0.850</td>
<td>41.463%</td>
<td>3.900</td>
<td>P = &lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>1.200 ± 0.696</td>
<td>0.156</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Atitrusha 0 – 3 N = 17</td>
<td>BT</td>
<td>1.700 ± 0.923</td>
<td>0.206</td>
<td>0.750</td>
<td>44.117%</td>
<td>3.419</td>
<td>P = &lt;0.001</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>0.950 ± 0.759</td>
<td>0.170</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dourbalya 0 – 3 N = 11</td>
<td>BT</td>
<td>1.050 ± 1.050</td>
<td>0.235</td>
<td>0.350</td>
<td>33.333%</td>
<td>2.070</td>
<td>P = 0.063</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>0.700 ± 0.923</td>
<td>0.206</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mukatalu shosha 0 – 2 N = 13</td>
<td>BT</td>
<td>0.850 ± 0.745</td>
<td>0.167</td>
<td>0.450</td>
<td>52.941%</td>
<td>2.714</td>
<td>P = 0.008</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AT</td>
<td>0.400 ± 0.503</td>
<td>0.112</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karapada BT</td>
<td>1.200 ± 1.152</td>
<td>0.258</td>
<td>0.400</td>
<td>33.333%</td>
<td>2.828</td>
<td>P = 0.008</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DISCUSSION:

Abhrakabhasmadi yoga is explained in prameha roga adhikara in Yogaratanakara and consists of haritaki, vibhitaki, amalaka, hardira and abhraka bhasma. All the 5 drugs, individually are Pramehagna as explained in the samhithas and various research studies\textsuperscript{11-13} have proved their hypoglycemic effect in diabetes.

Haritaki, Amalaki and Vibhitaki have balya, rasayana and dhatuvardhaka property, thus helps in rejuvenation of the cells and rectifying the khavaigunya in the rogadhisthaana. They are tridoshahara and help in rectifying dosha dushti and thus helps in samprapti vighatana. The chakshushya property of these 3 drugs may also benefit in preventing diabetic retinopathy. The kaphahara and medohara property of all the drugs, help in removing margavarana in the avaranaja variety. Hareetaki, vibhitaki and haridra have raksha guna thus is kapha, medohara helping in the samprapti vightana. Hareetaki, vibhitaki and haridra have ushna virya and thus helps in vata kaphaharana and reversal of samprapti. The trishna nigraha karma of haritaki is beneficial in managing atitrusha and mukhatalushosha. Vibhitaki has dhatuvardaka and mutradoshagna action. The dahaprashamana karma of amalaka is beneficial in reducing karapada daha and also trishna. Individual drugs of triphala contain glycosides, polyphenols, menthol, sorbitol alkaldoids, terpenoids, flavonoids, carotenoids etc and these are all frequently implicated to possess potential as anti diabetic and antioxidants. Ellagic acid in amalaki exerts antidiabetic activity though the action on beta cells of pancreas that stimulates insulin secretion and decreases glucose intolerance. Its important constituents including gallic acid, gallotanin, ellagic acid and corilagin possess antidiabetic effects through their antioxidant and free radical scavenging properties. It has also been reported to prevent/reduce hyperglycemia, cardiac complications, diabetic nephropathy, neuropathy, cataractogenesis and protein wasting.

Haridra has rasayana and balya property necessary for the rectification of the khavaigunya in the disease. Haridra has a tridoshashamaka effect useful in all varieties of Prameha. Haridra also has a mutrasangrahaniya quality. Haridra is considered to be the best agrya dravya in prameha. Active ingredient

### Table no. 3 Overall effect of treatment

<table>
<thead>
<tr>
<th>Remission</th>
<th>No. of patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mild</td>
<td>5</td>
<td>25%</td>
</tr>
<tr>
<td>Moderate</td>
<td>10</td>
<td>50%</td>
</tr>
<tr>
<td>Good</td>
<td>4</td>
<td>20%</td>
</tr>
<tr>
<td>Excellent</td>
<td>1</td>
<td>5%</td>
</tr>
</tbody>
</table>

*Wilcoxon signed rank test*
curcumin is said to be responsible for antidiabetic action, and this may be due to its potent ability to suppress oxidative stress and inflammation. It shows a beneficial role against advanced glycation as well as collagen crosslinking and through this way, mitigates advanced glycation end products – induced complications of diabetes. Curcumin also reduces blood glucose and the levels of glycosylated haemoglobin through regulation of polyol pathway.

The presence of major and minor elements like Fe, Al, Si, Mg, Ca in abhraka bhasma may balance the minerals in the body which are very essential for diabetic patient, which are excreted through improper metabolism and excessive urination. The electrolytes like Ca, Mg present in abhraka bhasma, are very much essential to the diabetics. Guru snigdha properties of abhraka bhasma along with its rasayana effect helps in normalcy of dhatus. It may have synergetic effect with other drugs in the formulation and also it may mimic the action of insulin in prameha, because most of the formulations used in treatment of prameha have abhraka as one of the ingredients. Abhraka may cause regeneration of islet of langherhans and induce secretion of insulin from pancreas.

Conclusion:

It can be concluded with statistical evidence that the formulation abhrakabhasmadi yoga that was selected for the study to evaluate the therapeutic effect in madhumeha type 2 diabetes mellitus proved very efficient in reducing plasma glucose levels and symptoms of madhumeha.

REFERENCES